RxDoctor Payments Data

John Brazill, MD

Anesthesiology · Bakersfield, CANPI 1144238429

Payments from drug & device makers

$9,572in general payments, 2019–2025

Across 313 payments — averaging $30.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Abbott$2K
  • Vertiflex, Inc.$2K
  • Nevro Corp.$458
  • Stimwave Technologies Incorporated$425
  • Medtronic$370
  • plus $210 from 7 others

What the payments were for

  • Travel & lodging$1,27413%
  • Food & beverage$8,29887%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,572 in reported general payments places this provider in the 95th percentile of 5,717 anesthesiology providers in California.

See all anesthesiology providers in California

Medicare billing

Part B allowed, 2024
$105,318
Medicare patients
288
Services billed
938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,391$70,444
OxycontinOxycodone Hcl117$60,805
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,046$34,979
Oxycodone Hcl949$29,793
Morphine Sulfate ErMorphine Sulfate913$20,778
Xtampza ErOxycodone Myristate25$14,276
Fentanyl156$11,766
Lidocaine53$11,046
Pregabalin229$7,996
Hydromorphone Hcl236$5,933
Gabapentin514$5,478
Morphine Sulfate134$4,838
Carisoprodol282$3,333
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl20$2,791
Tizanidine Hcl268$2,300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$20$14,27625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,717 anesthesiology providers in California.

Other anesthesiology in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →